B+
Bull case
25%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
SILO
SiloFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$0.42
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.24
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
This remains a cautious monitoring memo. The scheduled May 7, 2026 post-earnings follow-up could not be anchored to a company earnings release, 10-Q, or earnings 8-K in recent SEC filings checked through May 9, 2026, so earnings surprise, guidance revision, and analyst target-change signals are unavailable rather than positive. News flow in the packet is thin and generic, and the stock's move from the May 7 anchor price of $0.42 to about $0.405 on May 9 appears muted and not clearly earnings-linked. With low coverage, limited trusted secondary reaction, and a thesis still dominated by one clinical/regulatory milestone, confidence should stay capped.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystNon-core QwikAgents acquisition adds strategy and dilution scrutinyHigh impact
The April 2, 2026 8-K disclosed the purchase of QwikAgents software and related domains for 2.1 million common shares, a material issuance that may complicate the biotech thesis and investor positioning [#8-K-2026-04-02].
2026-12-31eventSPC-15 IND path remains the main value inflectionHigh impact
The 2026 10-K says SPC-15 had a pre-IND meeting with FDA in September 2024, GLP pharmacokinetic/pharmacodynamic and toxicology work is underway, and management is aiming for an IND submission in 2026 [#10-K-2026-03-27].
2027-03-27catalystNear-term liquidity pressure is lower than in prior going-concern periodsHigh impact
The 2026 10-K reported working capital of $6.7 million at December 31, 2025 and stated cash was sufficient to meet obligations for at least twelve months from the filing date, which reduces immediate balance-sheet stress even if it does not remove future financing risk [#10-K-2026-03-27].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology